CYFLOX 500 Tablet is a pharmaceutical-grade antimicrobial agent formulated with Ciprofloxacin 500 mg, a second-generation fluoroquinolone antibiotic. As an advanced oral treatment option for a wide variety of bacterial infections, it is recognized globally for its rapid action and exceptional therapeutic efficacy against both gram-positive and gram-negative pathogens.

Ciprofloxacin acts by inhibiting two essential bacterial enzymes—DNA gyrase and topoisomerase IV—that are vital for DNA replication, transcription, and repair. This interference results in the disruption of bacterial DNA processes and leads to cell death, making Ciprofloxacin a bactericidal agent. Its mechanism is effective even against bacteria that are resistant to other antibiotic classes like penicillins or cephalosporins.

CYFLOX 500 Tablet is recommended for the treatment of:

Lower and upper urinary tract infections (including pyelonephritis and prostatitis)

Lower respiratory tract infections (chronic bronchitis, pneumonia)

Skin and soft tissue infections (wound infections, cellulitis)

Bone and joint infections (osteomyelitis)

Gastrointestinal infections (infectious diarrhea, typhoid, shigellosis)

Sexually transmitted diseases (gonorrhea)

Infections caused by multidrug-resistant organisms

Anthrax post-exposure prophylaxis (as per CDC guidelines)

This 500 mg strength is particularly suitable for moderate to severe infections or infections that require extended coverage with high serum levels of the drug. It can also serve as a convenient step-down therapy for hospitalized patients transitioning from IV antibiotics to oral dosage.

Pharmacokinetics and Bioavailability

CYFLOX 500 offers excellent oral bioavailability of over 70% and is rapidly absorbed, with peak plasma concentrations reached within 1–2 hours. It has a half-life of approximately 4 hours and demonstrates extensive tissue distribution, including into the lungs, kidneys, liver, prostate, and bones, making it suitable for deep-seated infections.

The drug is excreted primarily via the kidneys, which means dose adjustment is recommended in patients with renal impairment. It may also be co-prescribed with other agents in dual therapy for complicated infections or hospital-acquired cases.

Manufacturing Highlights by BluepillExpress

WHO-GMP certified manufacturing facilities with EU-GMP, PICS, and USFDA-readiness

In-house QA/QC with HPLC assay, dissolution, and stability testing

Customizable packaging (Alu-Alu, blister, strip packs, HDPE)

Export support including COA, MSDS, MOA, stability data, and full dossier

Private labeling and bulk manufacturing services

Batch size flexibility and MOQ-based pricing for international buyers